Form 4 for ACRV Acrivon Therapeutics, Inc.
Accepted 2022-11-16 00:00:00 ET · period of report 2022-11-14 · accession 0001209191-22-057395 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2022-11-16 | 2022-11-14 | ACRV | Blume-Jensen Peter | Pres, CEO, Dir | A - Grant | $0.00 | +1.50M | 2.37M | +172% | $0 |
| DI | 2022-11-16 | 2022-11-14 | ACRV | Blume-Jensen Peter | Pres, CEO, Dir | A - Grant | $0.00 | +26.7K | 320.7K | +9% | $0 |
| D | 2022-11-16 | 2022-11-14 | ACRV | Blume-Jensen Peter | Pres, CEO, Dir | A - Grant | $0.00 | +180.3K | 180.3K | New | $0 |
| DI | 2022-11-16 | 2022-11-14 | ACRV | Blume-Jensen Peter | Pres, CEO, Dir | A - Grant | $0.00 | +80.1K | 80.1K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-11-14 | A | A | 503,419 | $0.00 | 2,310,007 | D | — | — | |
| 2 | Common | Common Stock | 2022-11-14 | A | A | 934,731 | $0.00 | 1,806,588 | D See footnote | — | — | (F5) These securities are held by Dr. Blume-Jensen's spouse. Dr. Blume-Jensen disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. |
| 3 | Common | Common Stock | 2022-11-14 | A | A | 26,707 | $0.00 | 320,705 | I | — | — | |
| 4 | Common | Common Stock | 2022-11-14 | A | A | 60,090 | $0.00 | 2,370,097 | D | — | — | |
| 5 | Derivative | Stock Option (Right to Buy) | 2022-11-14 | A | A | 180,269 | $0.00 | 180,269 | D See footnote | $12.50 · — to 2032-11-13 | 180,269 Common Stock | (F5) These securities are held by Dr. Blume-Jensen's spouse. Dr. Blume-Jensen disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. (F6) Twenty-five percent (25%) of the shares subject to the option shall vest on the one-year anniversary of the grant date, and the remaining shares subject to the option shall vest in 36 equal monthly installments thereafter, in each case subject to the Reporting Person's continuous service through each such vesting date. |
| 6 | Derivative | Stock Option (Right to Buy) | 2022-11-14 | A | A | 80,120 | $0.00 | 80,120 | I | $12.50 · — to 2032-11-13 | 80,120 Common Stock | (F6) Twenty-five percent (25%) of the shares subject to the option shall vest on the one-year anniversary of the grant date, and the remaining shares subject to the option shall vest in 36 equal monthly installments thereafter, in each case subject to the Reporting Person's continuous service through each such vesting date. |